• Policy
• Antiemetic Emend's generic benefit after 15 yrs since origin
• by Lee, Tak-Sun Sep 7, 2022 05:51am

• Policy
• Enactment of preferential pricing sublaws slow
• by Lee, Jeong-Hwan Sep 6, 2022 05:51am

• Policy
• The goal shorten the development of mRNA vaccine to 100 days
• by Lee, Hye-Kyung Sep 6, 2022 05:51am

• Policy
• Checking the effectiveness of SKYCovione,
• by Kim, Jung-Ju Sep 6, 2022 05:51am

• Policy
• Including SKYCovione, 6 types of COVID-19 vaccines
• by Lee, Jeong-Hwan Sep 6, 2022 05:51am

• Policy
• Drugs granted conditional approv to report clinical progress
• by Lee, Hye-Kyung Sep 5, 2022 05:55am

• Policy
• MFDS has launched permission review for Pfizer Comirnaty 2
• by Kim, Jung-Ju Sep 5, 2022 05:55am

• Policy
• Will Migraine drug Ajovy be reimbursed following Emgality?
• by Lee, Tak-Sun Sep 2, 2022 06:03am

• Policy
• The MFDS reviews Pfizer's vaccine permission for infants
• by Lee, Hye-Kyung Sep 2, 2022 06:03am

• Policy
• Tylenol ER, voluntarily withdrawn, will be maintained
• by Kim, Jung-Ju Sep 2, 2022 06:03am